Indeed, targeting of TAM reprogramming via IL-6 inhibition with CD40 stimulation (84), SLIT2 inhibition (70), and MAGL inhibition (81) exhibits robust synergy with ICIs (e.g., anti–PD-1, anti-CTLA4, and anti–4-1BB) in preclinical GBM models. The gene discussed is SLIT2; the disease is glioblastoma.